Rankings
▼
Calendar
COLL (Collegium Pharmaceutical, Inc.) Stock Financials & Earnings | Market Cap Arena
COLL
Collegium Pharmaceutical, Inc.
Mkt Cap
$1B
Healthcare
·
Drug Manufacturers - Specialty & Generic
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$781M
Net Income (TTM)
$63M
EPS (TTM)
$1.71
Free Cash Flow (TTM)
$328M
Gross Margin
59.3%
Op. Margin
23.0%
Net Margin
8.1%
FCF Margin
42.0%
P/S Ratio (TTM)
1.5x
P/E Ratio (TTM)
18.9x
YoY Rev Growth
+23.6%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$145M
$77M
$25M
Q2 23
$136M
$74M
$36M
Q3 23
$137M
$80M
$45M
Q4 23
$150M
$95M
$62M
Q1 24
$145M
$91M
$49M
Q2 24
$145M
$91M
$47M
Q3 24
$159M
$97M
$35M
Q4 24
$182M
$98M
$38M
Q1 25
$178M
$97M
$22M
Q2 25
$188M
$108M
$35M
Q3 25
$209M
$129M
$64M
Q4 25
$205M
$128M
$59M
marketcaparena.com
Revenue Breakdown
COLL
Collegium Pharmaceutical, Inc.
Revenue Breakdown
Q4 2025
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
2.3x
—
Q2 23
2.2x
—
Q3 23
2.2x
131.5x
Q4 23
2.1x
24.6x
Q1 24
2.1x
12.7x
Q2 24
2.1x
11.9x
Q3 24
2.0x
13.4x
Q4 24
1.9x
17.1x
Q1 25
1.8x
27.0x
Q2 25
1.7x
32.7x
Q3 25
1.6x
20.3x
Q4 25
1.5x
18.9x
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
$28M
$27M
Q2 23
$100M
$100M
Q3 23
$74M
$74M
Q4 23
$73M
$73M
Q1 24
$62M
$61M
Q2 24
$67M
$67M
Q3 24
-$9M
-$9M
Q4 24
$85M
$84M
Q1 25
$55M
$55M
Q2 25
$72M
$72M
Q3 25
$78M
$78M
Q4 25
$123M
$122M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$176K
Q2 23
$56K
Q3 23
$65K
Q4 23
$164K
Q1 24
$568K
Q2 24
$270K
Q3 24
$244K
Q4 24
$570K
Q1 25
$798K
Q2 25
$65K
Q3 25
$188K
Q4 25
$689K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
+72.9%
+28.1%
Q2 23
+9.7%
-11.1%
Q3 23
+7.6%
-13.9%
Q4 23
+15.5%
-25.3%
Q1 24
+0.1%
-20.6%
Q2 24
+7.2%
-2.1%
Q3 24
+16.5%
+35.7%
Q4 24
+21.5%
+63.3%
Q1 25
+22.7%
+63.5%
Q2 25
+29.4%
+56.3%
Q3 25
+31.4%
+17.1%
Q4 25
+12.9%
+1.7%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$6M
4.2%
Q2 23
$0
0.0%
Q3 23
$7M
5.1%
Q4 23
$7M
4.7%
Q1 24
$7M
5.2%
Q2 24
$10M
6.9%
Q3 24
$7M
4.6%
Q4 24
$8M
4.2%
Q1 25
$12M
6.5%
Q2 25
$11M
5.8%
Q3 25
$10M
4.7%
Q4 25
$10M
4.7%
marketcaparena.com
OpEx Breakdown
G&A
S&M
SG&A
Quarter
G&A
S&M
SG&A
Q1 23
—
—
$53M
Q2 23
—
—
$38M
Q3 23
—
—
$35M
Q4 23
$26M
$7M
—
Q1 24
—
—
$42M
Q2 24
—
—
$43M
Q3 24
—
—
$62M
Q4 24
—
—
$63M
Q1 25
—
—
$76M
Q2 25
—
—
$74M
Q3 25
—
—
$66M
Q4 25
—
—
$68M
marketcaparena.com
Revenue Segments
Belbuca
Nucynta ER
Nucynta IR
Symproic
Xtampza ER
Quarter
Belbuca
Nucynta ER
Nucynta IR
Symproic
Xtampza ER
Q1 23
$44M
$21M
$28M
$4M
$48M
Q2 23
$43M
$19M
$28M
$4M
$41M
Q3 23
$45M
$23M
$25M
$4M
$40M
Q1 24
$51M
$19M
$26M
$3M
$46M
Q2 24
$52M
$19M
$25M
$4M
$45M
Q3 24
$53M
$20M
$25M
$4M
$49M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$269M
$0
$269M
Q2 23
$284M
$42M
$325M
Q3 23
$259M
$46M
$305M
Q4 23
$239M
$72M
$311M
Q1 24
$229M
$89M
$318M
Q2 24
$173M
$99M
$272M
Q3 24
$39M
$81M
$120M
Q4 24
$71M
$92M
$163M
Q1 25
$96M
$102M
$198M
Q2 25
$117M
$105M
$222M
Q3 25
$170M
$136M
$306M
Q4 25
$251M
$155M
$407M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
34M
+2.2%
Q2 23
43M
+24.9%
Q3 23
42M
-1.8%
Q4 23
41M
-1.9%
Q1 24
41M
+0.4%
Q2 24
40M
-2.5%
Q3 24
40M
-0.5%
Q4 24
40M
-0.1%
Q1 25
33M
-18.1%
Q2 25
39M
+19.0%
Q3 25
39M
+0.9%
Q4 25
40M
+0.7%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
—
—
FY 15
$0
46
FY 16
$11K
150
FY 17
$190K
150
FY 18
$2M
150
FY 19
$1M
255
FY 20
$1M
234
FY 21
$2M
152
FY 22
$2M
207
FY 23
$3M
197
FY 24
$2M
357
FY 25
$2M
423
marketcaparena.com